| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
Purity: ≥98%
SNU-0039 (DWK-133) is an orally bioavailable inhibitor of β-amyloid protein aggregation with the potential to be used as an anti-Alzheimer's agent.
| ln Vitro |
MDR-1339 is an Aβ aggregation inhibitor that modestly inhibits CYP2C8 (IC50, 31.4 μM) but has no discernible inhibitory impact on a set of CYP isoenzymes. MDR-1339 (3.1-50 μM) depolymerizes Aβ fibrils and inhibits Aβ aggregation formation in a dose-dependent manner. Additionally, MDR-1339 (1.5–10 μM) shields cells from the toxicity caused by Aβ [1].
|
|---|---|
| ln Vivo |
In a mouse model of Alzheimer's disease (AD), MDR-1339 (0.1-10 mg/kg, orally) with an ED50 of 0.19 mg/kg dose-dependently restores passive avoidance reflexes. MDR-1339, given orally to APP/PS1 mice every day for eight weeks at doses of 30 and 100 mg/kg, dramatically enhanced spontaneous alternation and decreased Aβ1-40 and Aβ1-42 levels [1].
|
| References |
| Molecular Formula |
C20H22O4
|
|---|---|
| Molecular Weight |
326.39
|
| Exact Mass |
326.152
|
| CAS # |
1018946-38-7
|
| Related CAS # |
1018946-38-7;
|
| PubChem CID |
24764491
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.696
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
24
|
| Complexity |
375
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
CUEPJIGXQLIOIK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H22O4/c1-21-10-4-5-14-6-8-17-16(11-14)13-19(24-17)15-7-9-18(22-2)20(12-15)23-3/h6-9,11-13H,4-5,10H2,1-3H3
|
| Chemical Name |
2-(3,4-Dimethoxyphenyl)-5-(3-methoxypropyl) benzofuran
|
| Synonyms |
SNU0039 DWK1339SNU 0039 DWK 1339SNU-0039 DWK-1339
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~153.19 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (7.66 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.66 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0638 mL | 15.3191 mL | 30.6382 mL | |
| 5 mM | 0.6128 mL | 3.0638 mL | 6.1276 mL | |
| 10 mM | 0.3064 mL | 1.5319 mL | 3.0638 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA